T20QoL: an observational multicenter cohort study to evaluate the quality of life in HIV-patients treated with enfuvirtide (ENF, T-20) in combination with an optimized background therapy

R Bucciardini1, M Massella1, A Corpolongo2, P Narciso2, V Fragola1, M Mirra1, S Donnini1, O Vigan&ograve;3, S Costarelli4, V Tozzi21Istituto Superiore di Sanit&agrave;, Rome, Italy; 2IRCCS L. Spallanzani, Rome, Italy; 3Ospedale L. Sacco, Milan, Italy; 4Spedali Civili di Brescia, Bres...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	R Bucciardini, M Massella, A Corpolongo, P Narciso, V Fragola, et al
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2008
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/125c94dab8824fc496cf3fab2cd41b69
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:125c94dab8824fc496cf3fab2cd41b69
record_format	dspace
spelling	oai:doaj.org-article:125c94dab8824fc496cf3fab2cd41b692021-12-02T00:55:04ZT20QoL: an observational multicenter cohort study to evaluate the quality of life in HIV-patients treated with enfuvirtide (ENF, T-20) in combination with an optimized background therapy1177-54751177-5491https://doaj.org/article/125c94dab8824fc496cf3fab2cd41b692008-09-01T00:00:00Zhttp://www.dovepress.com/t20qol-an-observational-multicenter-cohort-study-to-evaluate-the-quali-a2307https://doaj.org/toc/1177-5475https://doaj.org/toc/1177-5491R Bucciardini1, M Massella1, A Corpolongo2, P Narciso2, V Fragola1, M Mirra1, S Donnini1, O Vigan&ograve;3, S Costarelli4, V Tozzi21Istituto Superiore di Sanit&agrave;, Rome, Italy; 2IRCCS L. Spallanzani, Rome, Italy; 3Ospedale L. Sacco, Milan, Italy; 4Spedali Civili di Brescia, Brescia, ItalyAim: To evaluate the impact of health-related quality of life (HRQoL) enfuvirtide-based (ENF-based) salvage regimens of treatment-experienced HIV patients, in an observational multicenter cohort study.Methods: HRQoL was measured in a cohort of 16 patients over a 6-month follow-up using 2 instruments: the ISSQoL (Istituto Superiore di Sanit&agrave; Quality of Life), a recently validated HIV-specific questionnaire; the EQ-5D (EuroQol), a generic widely used instrument. ENF was given at standard dosage along with an optimized background regimen.Results: Most of HRQoL dimensions showed improvement in ENF-treated patients at the post-baseline time points. Social functioning was the only dimension showing a negative effect. Monthly care costs of antiretroviral drugs for HIV patients taking ENF plus an optimized background regimen were approximately &euro;2,348 per patient-month (range &euro;382&ndash; &euro;2,940).Conclusion: Our results show that the addition of ENF to an optimized background salvage-HAART may positively affect HRQoL not only in clinical trials but also in a sample population of patients used in a routine clinical practice.Keywords: enfuvirtide, HRQoL, HIV R BucciardiniM MassellaA CorpolongoP NarcisoV Fragolaet alDove Medical PressarticleMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol 2008, Iss Issue 3, Pp 577-581 (2008)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 R Bucciardini M Massella A Corpolongo P Narciso V Fragola et al T20QoL: an observational multicenter cohort study to evaluate the quality of life in HIV-patients treated with enfuvirtide (ENF, T-20) in combination with an optimized background therapy
description	R Bucciardini1, M Massella1, A Corpolongo2, P Narciso2, V Fragola1, M Mirra1, S Donnini1, O Vigan&ograve;3, S Costarelli4, V Tozzi21Istituto Superiore di Sanit&agrave;, Rome, Italy; 2IRCCS L. Spallanzani, Rome, Italy; 3Ospedale L. Sacco, Milan, Italy; 4Spedali Civili di Brescia, Brescia, ItalyAim: To evaluate the impact of health-related quality of life (HRQoL) enfuvirtide-based (ENF-based) salvage regimens of treatment-experienced HIV patients, in an observational multicenter cohort study.Methods: HRQoL was measured in a cohort of 16 patients over a 6-month follow-up using 2 instruments: the ISSQoL (Istituto Superiore di Sanit&agrave; Quality of Life), a recently validated HIV-specific questionnaire; the EQ-5D (EuroQol), a generic widely used instrument. ENF was given at standard dosage along with an optimized background regimen.Results: Most of HRQoL dimensions showed improvement in ENF-treated patients at the post-baseline time points. Social functioning was the only dimension showing a negative effect. Monthly care costs of antiretroviral drugs for HIV patients taking ENF plus an optimized background regimen were approximately &euro;2,348 per patient-month (range &euro;382&ndash; &euro;2,940).Conclusion: Our results show that the addition of ENF to an optimized background salvage-HAART may positively affect HRQoL not only in clinical trials but also in a sample population of patients used in a routine clinical practice.Keywords: enfuvirtide, HRQoL, HIV
format	article
author	R Bucciardini M Massella A Corpolongo P Narciso V Fragola et al
author_facet	R Bucciardini M Massella A Corpolongo P Narciso V Fragola et al
author_sort	R Bucciardini
title	T20QoL: an observational multicenter cohort study to evaluate the quality of life in HIV-patients treated with enfuvirtide (ENF, T-20) in combination with an optimized background therapy
title_short	T20QoL: an observational multicenter cohort study to evaluate the quality of life in HIV-patients treated with enfuvirtide (ENF, T-20) in combination with an optimized background therapy
title_full	T20QoL: an observational multicenter cohort study to evaluate the quality of life in HIV-patients treated with enfuvirtide (ENF, T-20) in combination with an optimized background therapy
title_fullStr	T20QoL: an observational multicenter cohort study to evaluate the quality of life in HIV-patients treated with enfuvirtide (ENF, T-20) in combination with an optimized background therapy
title_full_unstemmed	T20QoL: an observational multicenter cohort study to evaluate the quality of life in HIV-patients treated with enfuvirtide (ENF, T-20) in combination with an optimized background therapy
title_sort	t20qol: an observational multicenter cohort study to evaluate the quality of life in hiv-patients treated with enfuvirtide (enf, t-20) in combination with an optimized background therapy
publisher	Dove Medical Press
publishDate	2008
url	https://doaj.org/article/125c94dab8824fc496cf3fab2cd41b69
work_keys_str_mv	AT rbucciardini t20qolanobservationalmulticentercohortstudytoevaluatethequalityoflifeinhivpatientstreatedwithenfuvirtideenft20incombinationwithanoptimizedbackgroundtherapy AT mmassella t20qolanobservationalmulticentercohortstudytoevaluatethequalityoflifeinhivpatientstreatedwithenfuvirtideenft20incombinationwithanoptimizedbackgroundtherapy AT acorpolongo t20qolanobservationalmulticentercohortstudytoevaluatethequalityoflifeinhivpatientstreatedwithenfuvirtideenft20incombinationwithanoptimizedbackgroundtherapy AT pnarciso t20qolanobservationalmulticentercohortstudytoevaluatethequalityoflifeinhivpatientstreatedwithenfuvirtideenft20incombinationwithanoptimizedbackgroundtherapy AT vfragola t20qolanobservationalmulticentercohortstudytoevaluatethequalityoflifeinhivpatientstreatedwithenfuvirtideenft20incombinationwithanoptimizedbackgroundtherapy AT etal t20qolanobservationalmulticentercohortstudytoevaluatethequalityoflifeinhivpatientstreatedwithenfuvirtideenft20incombinationwithanoptimizedbackgroundtherapy
_version_	1718403362428289024

T20QoL: an observational multicenter cohort study to evaluate the quality of life in HIV-patients treated with enfuvirtide (ENF, T-20) in combination with an optimized background therapy

Ejemplares similares